← Leaderboards
Mary Cushman
University Of Vermont &St Agric College
$9,262,208
Attributed
$23,060,221
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $19.4M · FY2006–24$20M$15M$10M$5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$56,282,907 · 8
By mechanism
U01$21,502,903 · 2
P20$17,199,899 · 2
RF1$16,244,011 · 1
R01$1,060,166 · 1
K08$243,025 · 1
M01$32,903 · 1
Top collaborators
- Mark T Nelson7 shared
- George Howard6 shared
- Jennifer Jaie Manly6 shared
- Suzanne E Judd5 shared
- Allison E Aiello1 shared
- Virginia J. Howard1 shared
- Robert A Hummer1 shared
- Eric A. Whitsel1 shared
Most similar at University Of Vermont &St Agric College
Same institution · by research overlap
- Edwin Gladstone Bovill$1,425,488
- Kathleen E Brummel-Ziedins$1,741,228
- Edwin G Bovill$0
- Warren K Bickel$43,729,025
- George L Long$253,986
Others in their field
Top investigators on “Funding”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,479,940,681
- Leonard Freedman · Leidos Biomedical Research, Inc.$968,195,877
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Jeffrey P Krischer · University Of South Florida$358,470,093
Research focus
FundingStrokeImpaired CognitionRecruitCardiovascular SystemDementiaCardiovascular DiseasesResearch PersonnelMemberInnovationCollaborationsScientistPersonsAmericanBasic ScienceScienceCostBrain HealthCohortFutureDisabilityMultidisciplinaryResourcesInfrastructure
Grant awards (28)
Understanding Cohort Effects on Stroke, VCID, and Cognition After Major Epidemiologic Transitions$16,244,011
RF1 · FY2024 · NS
Vermont Center for Cardiovascular and Brain Health$2,307,350
P20 · FY2024 · GM · contact PI
Core A: Administrative Core$809,597
P20 · FY2024 · GM · contact PI
Vermont Center for Cardiovascular and Brain Health$2,307,350
P20 · FY2023 · GM · contact PI
Core A: Administrative Core$809,261
P20 · FY2023 · GM · contact PI
Vermont Center for Cardiovascular and Brain Health$660,479
P20 · FY2023 · GM · contact PI
Core A: Administrative Core$660,479
P20 · FY2023 · GM · contact PI
Vermont Center for Cardiovascular and Brain Health$272,427
P20 · FY2023 · GM · contact PI
VCID and Stroke in a Bi-racial National Cohort$2,574,046
U01 · FY2022 · NS
Vermont Center for Cardiovascular and Brain Health$2,315,833
P20 · FY2022 · GM · contact PI
Add Health as a Resource for the Science of the Exposome and Risk for AD/ADRD$1,070,406
U01 · FY2022 · AG
Core A: Administrative Core$725,033
P20 · FY2022 · GM · contact PI
VCID and Stroke in a Bi-racial National Cohort$3,187,727
U01 · FY2021 · NS
Vermont Center for Cardiovascular and Brain Health$2,322,405
P20 · FY2021 · GM · contact PI
Core A: Administrative Core$721,947
P20 · FY2021 · GM · contact PI
VCID and Stroke in a Bi-racial National Cohort$3,914,560
U01 · FY2020 · NS
Vermont Center for Cardiovascular and Brain Health$2,604,345
P20 · FY2020 · GM · contact PI
Core A: Administrative Core$683,393
P20 · FY2020 · GM · contact PI
VCID and Stroke in a Bi-racial National Cohort$4,806,568
U01 · FY2019 · NS
VCID and Stroke in a Bi-racial National Cohort$5,949,596
U01 · FY2018 · NS
Association of Thrombophilia and Inflammation with Post-Thrombotic Syndrome$333,660
R01 · FY2008 · HL · contact PI
Association of Thrombophilia and Inflammation with Post-Thrombotic Syndrome$370,291
R01 · FY2007 · HL · contact PI
Association of Thrombophilia and Inflammation with Post-Thrombotic Syndrome$356,215
R01 · FY2006 · HL · contact PI
PREVENT: PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM$0
M01 · FY2002 · RR
THROMBOSIS MARKERS OVER TIME IN CARDIOVASCULAR DISEASE$120,340
K08 · FY2001 · HL
THROMBOSIS MARKERS OVER TIME IN CARDIOVASCULAR DISEASE$122,685
K08 · FY2000 · HL
PREVENT: PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM$32,903
M01 · FY2000 · RR
PREVENT: PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM$0
M01 · FY2000 · RR